The empagliflozin-basal insulin group had a lower total number of hypoglycaemic episodes, patients with 1 or ≥2 episodes, hypoglycaemia incidence rate, and patients with any level 1 hypoglycaemia. This evidence concerns the gene INS and Hypoglycemia.